Lung Therapeutics announced that the Food & Drug Administration (FDA) has granted Orphan Drug designation to its lead drug candidate, LTI-01 for the treatment of empyema, a typical complication of pneumonia.
LTI-01 is an injectable, fibronolytic drug that maximizes scar removal around the lungs, thus promoting fluid drainage while minimizing bleeding risk and other complications.
Lung Therapeutics currently has pipeline programs ongoing in three areas, LTI-01 in loculated pleural effusion (PE), LTI-02 in acute lung injury (ALI), and LTI-03 in idiopathic pulmonary fibrosis (IPF). LTI-03 has been shown to reverse belomycin-induced lung injury when given at seven or 14 days after induction of injury, and is currently being studied in additional tests.
For more information call (512) 872-7527 or visit LungTx.com.